DE60124863D1 - Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper - Google Patents

Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper

Info

Publication number
DE60124863D1
DE60124863D1 DE60124863T DE60124863T DE60124863D1 DE 60124863 D1 DE60124863 D1 DE 60124863D1 DE 60124863 T DE60124863 T DE 60124863T DE 60124863 T DE60124863 T DE 60124863T DE 60124863 D1 DE60124863 D1 DE 60124863D1
Authority
DE
Germany
Prior art keywords
against human
recombinant antibodies
human interleukin
beta recombinant
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60124863T
Other languages
English (en)
Other versions
DE60124863T3 (de
DE60124863T2 (de
Inventor
Hermann Gram
Padova E Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60124863(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60124863D1 publication Critical patent/DE60124863D1/de
Application granted granted Critical
Publication of DE60124863T2 publication Critical patent/DE60124863T2/de
Publication of DE60124863T3 publication Critical patent/DE60124863T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
DE60124863T 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper Expired - Lifetime DE60124863T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
GB0001448 2000-01-21
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (3)

Publication Number Publication Date
DE60124863D1 true DE60124863D1 (de) 2007-01-11
DE60124863T2 DE60124863T2 (de) 2007-04-26
DE60124863T3 DE60124863T3 (de) 2010-05-20

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124863T Expired - Lifetime DE60124863T3 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper

Country Status (33)

Country Link
US (4) US20030124617A1 (de)
EP (1) EP1248804B2 (de)
JP (2) JP3978338B2 (de)
KR (1) KR100697126B1 (de)
CN (1) CN1395581B (de)
AR (1) AR027253A1 (de)
AT (1) ATE346868T1 (de)
AU (1) AU772949B2 (de)
BR (1) BR0107661A (de)
CA (1) CA2396212C (de)
CO (1) CO5261584A1 (de)
CY (1) CY1107989T1 (de)
CZ (1) CZ302738B6 (de)
DE (1) DE60124863T3 (de)
DK (1) DK1248804T4 (de)
ES (1) ES2274865T5 (de)
GB (1) GB0001448D0 (de)
HK (1) HK1050013A1 (de)
HU (1) HUP0204156A3 (de)
IL (2) IL150551A0 (de)
MX (1) MXPA02007091A (de)
MY (1) MY155269A (de)
NO (1) NO329816B1 (de)
NZ (1) NZ519936A (de)
PE (1) PE20011219A1 (de)
PL (1) PL207642B1 (de)
PT (1) PT1248804E (de)
RU (1) RU2264413C2 (de)
SI (1) SI1248804T2 (de)
SK (1) SK288054B6 (de)
TR (1) TR200201780T2 (de)
WO (1) WO2001053353A2 (de)
ZA (1) ZA200205659B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1297142B1 (de) 2000-06-29 2009-01-14 Abbott Laboratories Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2280286A1 (de) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Verfahren zur Verwendung von Zytokin-Assays zur Diagnose, Behandlung und Beurteilung von Systemischem Lupus Erythematosus
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP1851245B1 (de) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antikörper gegen interleukin-1-beta
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
ES2944067T3 (es) * 2005-10-26 2023-06-19 Novartis Ag Uso de anticuerpos anti il-1beta
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
WO2008106131A2 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
CA3213888A1 (en) * 2007-05-29 2008-12-04 Novartis Ag New indications for anti-il-i-beta therapy
CA2710252C (en) * 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
CN103328511B (zh) * 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
PL2578688T5 (pl) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. Myszy adam6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
SG10201708562VA (en) 2012-02-13 2017-12-28 Agency Science Tech & Res IL-1β Neutralizing Human Monoclonal Antibodies
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DE60124863T3 (de) 2010-05-20
CN1395581A (zh) 2003-02-05
GB0001448D0 (en) 2000-03-08
HK1050013A1 (zh) 2003-06-06
PL356297A1 (en) 2004-06-28
CZ20022531A3 (cs) 2002-10-16
HUP0204156A3 (en) 2005-09-28
IL150551A0 (en) 2003-02-12
SK10352002A3 (sk) 2003-03-04
CZ302738B6 (cs) 2011-10-12
WO2001053353A2 (en) 2001-07-26
PL207642B1 (pl) 2011-01-31
AR027253A1 (es) 2003-03-19
JP3978338B2 (ja) 2007-09-19
ES2274865T5 (es) 2010-04-19
EP1248804A2 (de) 2002-10-16
ES2274865T3 (es) 2007-06-01
CN1395581B (zh) 2010-10-13
MY155269A (en) 2015-09-30
DK1248804T3 (da) 2007-02-26
PT1248804E (pt) 2007-02-28
EP1248804B1 (de) 2006-11-29
SK288054B6 (sk) 2013-03-01
NZ519936A (en) 2004-02-27
JP2007097598A (ja) 2007-04-19
US20110182894A1 (en) 2011-07-28
CA2396212C (en) 2013-04-02
US7491392B2 (en) 2009-02-17
ATE346868T1 (de) 2006-12-15
ZA200205659B (en) 2003-12-31
KR100697126B1 (ko) 2007-03-20
DE60124863T2 (de) 2007-04-26
CY1107989T1 (el) 2013-09-04
US20090232803A1 (en) 2009-09-17
HUP0204156A2 (hu) 2003-03-28
AU3369701A (en) 2001-07-31
NO20023266L (no) 2002-08-28
RU2002121649A (ru) 2004-03-10
BR0107661A (pt) 2002-11-19
JP2003520595A (ja) 2003-07-08
NO329816B1 (no) 2010-12-27
CA2396212A1 (en) 2001-07-26
US20060251660A1 (en) 2006-11-09
CO5261584A1 (es) 2003-03-31
NO20023266D0 (no) 2002-07-05
KR20020073178A (ko) 2002-09-19
PE20011219A1 (es) 2001-12-17
SI1248804T2 (sl) 2010-04-30
TR200201780T2 (tr) 2003-01-21
US20030124617A1 (en) 2003-07-03
EP1248804B2 (de) 2009-12-02
IL150551A (en) 2010-11-30
RU2264413C2 (ru) 2005-11-20
WO2001053353A3 (en) 2002-04-04
DK1248804T4 (da) 2010-04-06
SI1248804T1 (sl) 2007-06-30
AU772949B2 (en) 2004-05-13
MXPA02007091A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
ATE471344T1 (de) Antikörper gegen vla-1
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
DE60239918D1 (de) Künstlicher Wirbel
DE60135144D1 (de) Verbinder
DE60143422D1 (de) Verbinder
NO20030823D0 (no) Vaksiner
DE60124662T8 (de) Karosseriestruktur
ATE464068T1 (de) Antikörper gegen opgl
NO20031705L (no) Vaksiner
DE60115555D1 (de) Funduskamera
DE60102506D1 (de) Verbinder
DE60106800D1 (de) Funduskamera
ATE267429T1 (de) Übereinstimmungssteuerverfahren
DE50209245D1 (de) Neuroprotektives medikament
DE60119875D1 (de) Verbinder
DE60142401D1 (de) Verbindungsverfahren
DE60112673D1 (de) Verbinder
DE50100088D1 (de) Irisblende
DE60102459D1 (de) Lockenwickler
DE60128315D1 (de) Funduskamera
DE60100973D1 (de) Verbinder
FR2803509B1 (fr) Prothese metatarso-phalangienne
DE60112629D1 (de) Dokumentausrichtung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN